Forty Seven【FTSV】銘柄情報

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

プレミアム

通貨

95.51

買値

95.51

売値

95.49

出来高

0.00 日の範囲 0.00

0.00 52 週間の範囲 0.00

前日終値

95.51

始値

時刻

最終取引時間

平均取引量 (3 か月)

財務取引量

VWAP

Forty Seven, Inc. Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Business Highlights

-- Presented Updated Data for Magrolimab Showing Robust, Durable Activity in MDS and AML Presented Foundational Preclinical Data for FSI-174 and Entered into Collaborations with bluebird bio and...

Forty Seven and Rocket Pharmaceuticals Announce Research Collaboration for Fanconi Anemia

MENLO PARK, Calif. and NEW YORK, March 11, 2020 (GLOBE NEWSWIRE) -- Forty Seven, Inc. (Nasdaq: FTSV) and Rocket Pharmaceuticals, Inc. (Nasdaq: RCKT) announced today that they have entered into a...

Moore Kuehn Encourages FTSV, MINI, POPE, WAAS, and TLRA Investors to Contact Law Firm

Moore Kuehn Encourages FTSV, MINI, POPE, WAAS, and TLRA Investors to Contact Law Firm PR Newswire NEW YORK, March 4, 2020 NEW YORK, March 4, 2020 /PRNewswire/ -- Moore Kuehn, PLLC, a securities...

SHAREHOLDER ALERT: WeissLaw LLP Investigates Forty Seven, Inc.

SHAREHOLDER ALERT: WeissLaw LLP Investigates Forty Seven, Inc. PR Newswire NEW YORK, March 3, 2020 NEW YORK, March 3, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of...

(FTSV) Alert: Johnson Fistel Investigates Proposed Sale of Forty Seven, Inc.; Are Shareholders Getting a Fair Deal?

(FTSV) Alert: Johnson Fistel Investigates Proposed Sale of Forty Seven, Inc.; Are Shareholders Getting a Fair Deal? PR Newswire SAN DIEGO, March 2, 2020 SAN DIEGO, March 2, 2020 /PRNewswire/...

Gilead to Acquire Forty Seven for $4.9 Billion

– Gilead Gains Forty Seven’s Investigational Immuno-Oncology Therapy in Multiple Clinical Studies for Diseases Including Myelodysplastic Syndrome, Acute Myeloid Leukemia and Diffuse Large B-Cell...

Forty Seven to Present at Upcoming Investor Conferences in March

MENLO PARK, Calif., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Forty Seven, Inc. (Nasdaq:FTSV), a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the...

Forty Seven to Present at Upcoming Investor Conferences in February

MENLO PARK, Calif., Feb. 06, 2020 (GLOBE NEWSWIRE) -- Forty Seven, Inc. (Nasdaq:FTSV), a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the...

Forty Seven Announces 2020 Strategic Priorities and Expected Milestones

-- Registration-Enabling Programs in MDS and DLBCL On-Track; Initiation of Phase 3 ENHANCE Trial in MDS and Phase 3 Trial in DLBCL Expected in 1Q and 2Q 2020 -- -- Updated Data from Ongoing Phase...

Forty Seven, Inc. Announces Closing of Underwritten Public Offering and Exercise in Full of Option to Purchase Additional Sha...

MENLO PARK, Calif., Dec. 16, 2019 (GLOBE NEWSWIRE) -- Forty Seven, Inc. (Nasdaq: FTSV), a clinical stage immuno-oncology company, today announced the closing of its previously announced public...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

出来高
値上がり率
値下がり率

銘柄コード	株価	出来高
WORXSCWorx Corporation	US$ 2.2001 (124.50%)	139.26M
CRNCCerence Inc	US$ 5.8566 (107.68%)	73.92M
ARQQArqit Quantum Inc	US$ 10.75 (46.46%)	805.53k
PROCProcaps Group SA	US$ 0.8202 (43.52%)	1.32M
SMSTDefiance Daily Target 2x Short MSTR ETF	US$ 6.585 (37.76%)	65.6M
SKKSKK Holdings Limited	US$ 0.9195 (-79.84%)	30.39M
TMTCTMT Acquisition Corporation	US$ 2.18 (-66.15%)	423.93k
WCTWellchange Holdings Company Limited	US$ 1.21 (-63.55%)	2.07M
TMTCUTMT Acquisition Corporation	US$ 2.99 (-55.24%)	11.76k
GLXGGalaxy Payroll Group Ltd	US$ 1.9596 (-49.88%)	2.29M
CDTConduit Pharmaceuticals Inc	US$ 0.1053 (14.08%)	564.07M
NVDANVIDIA Corporation	US$ 147.86 (1.35%)	354.6M
ELABElevai Labs Inc	US$ 0.02025 (-5.37%)	230.7M
AKTSAkoustis Technologies Inc	US$ 0.1055 (21.13%)	204.39M
MARAMARA Holdings Inc	US$ 24.1793 (6.85%)	151.45M